Cargando…
Does the cytokine adsorber CytoSorb(®) reduce vancomycin exposure in critically ill patients with sepsis or septic shock? a prospective observational study
BACKGROUND: Hemadsorption of cytokines is used in critically ill patients with sepsis or septic shock. Concerns have been raised that the cytokine adsorber CytoSorb(®) unintentionally adsorbs vancomycin. This study aimed to quantify vancomycin elimination by CytoSorb(®). METHODS: Critically ill pati...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9124739/ https://www.ncbi.nlm.nih.gov/pubmed/35599248 http://dx.doi.org/10.1186/s13613-022-01017-5 |
_version_ | 1784711789438566400 |
---|---|
author | Scharf, Christina Weinelt, Ferdinand Schroeder, Ines Paal, Michael Weigand, Michael Zoller, Michael Irlbeck, Michael Kloft, Charlotte Briegel, Josef Liebchen, Uwe |
author_facet | Scharf, Christina Weinelt, Ferdinand Schroeder, Ines Paal, Michael Weigand, Michael Zoller, Michael Irlbeck, Michael Kloft, Charlotte Briegel, Josef Liebchen, Uwe |
author_sort | Scharf, Christina |
collection | PubMed |
description | BACKGROUND: Hemadsorption of cytokines is used in critically ill patients with sepsis or septic shock. Concerns have been raised that the cytokine adsorber CytoSorb(®) unintentionally adsorbs vancomycin. This study aimed to quantify vancomycin elimination by CytoSorb(®). METHODS: Critically ill patients with sepsis or septic shock receiving continuous renal replacement therapy and CytoSorb(®) treatment during a prospective observational study were included in the analysis. Vancomycin pharmacokinetics was characterized using population pharmacokinetic modeling. Adsorption of vancomycin by the CytoSorb(®) was investigated as linear or saturable process. The final model was used to derive dosing recommendations based on stochastic simulations. RESULTS: 20 CytoSorb(®) treatments in 7 patients (160 serum samples/24 during CytoSorb(®)-treatment, all continuous infusion) were included in the study. A classical one-compartment model, including effluent flow rate of the continuous hemodialysis as linear covariate on clearance, best described the measured concentrations (without CytoSorb(®)). Significant adsorption with a linear decrease during CytoSorb(®) treatment was identified (p < 0.0001) and revealed a maximum increase in vancomycin clearance of 291% (initially after CytoSorb(®) installation) and a maximum adsorption capacity of 572 mg. For a representative patient of our cohort a reduction of the area under the curve (AUC) by 93 mg/L*24 h during CytoSorb(®) treatment was observed. The additional administration of 500 mg vancomycin over 2 h during CytoSorb(®) attenuated the effect and revealed a negligible reduction of the AUC by 4 mg/L*24 h. CONCLUSION: We recommend the infusion of 500 mg vancomycin over 2 h during CytoSorb(®) treatment to avoid subtherapeutic concentrations. Trial registration NCT03985605. Registered 14 June 2019, https://clinicaltrials.gov/ct2/show/NCT03985605 |
format | Online Article Text |
id | pubmed-9124739 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-91247392022-05-24 Does the cytokine adsorber CytoSorb(®) reduce vancomycin exposure in critically ill patients with sepsis or septic shock? a prospective observational study Scharf, Christina Weinelt, Ferdinand Schroeder, Ines Paal, Michael Weigand, Michael Zoller, Michael Irlbeck, Michael Kloft, Charlotte Briegel, Josef Liebchen, Uwe Ann Intensive Care Research BACKGROUND: Hemadsorption of cytokines is used in critically ill patients with sepsis or septic shock. Concerns have been raised that the cytokine adsorber CytoSorb(®) unintentionally adsorbs vancomycin. This study aimed to quantify vancomycin elimination by CytoSorb(®). METHODS: Critically ill patients with sepsis or septic shock receiving continuous renal replacement therapy and CytoSorb(®) treatment during a prospective observational study were included in the analysis. Vancomycin pharmacokinetics was characterized using population pharmacokinetic modeling. Adsorption of vancomycin by the CytoSorb(®) was investigated as linear or saturable process. The final model was used to derive dosing recommendations based on stochastic simulations. RESULTS: 20 CytoSorb(®) treatments in 7 patients (160 serum samples/24 during CytoSorb(®)-treatment, all continuous infusion) were included in the study. A classical one-compartment model, including effluent flow rate of the continuous hemodialysis as linear covariate on clearance, best described the measured concentrations (without CytoSorb(®)). Significant adsorption with a linear decrease during CytoSorb(®) treatment was identified (p < 0.0001) and revealed a maximum increase in vancomycin clearance of 291% (initially after CytoSorb(®) installation) and a maximum adsorption capacity of 572 mg. For a representative patient of our cohort a reduction of the area under the curve (AUC) by 93 mg/L*24 h during CytoSorb(®) treatment was observed. The additional administration of 500 mg vancomycin over 2 h during CytoSorb(®) attenuated the effect and revealed a negligible reduction of the AUC by 4 mg/L*24 h. CONCLUSION: We recommend the infusion of 500 mg vancomycin over 2 h during CytoSorb(®) treatment to avoid subtherapeutic concentrations. Trial registration NCT03985605. Registered 14 June 2019, https://clinicaltrials.gov/ct2/show/NCT03985605 Springer International Publishing 2022-05-23 /pmc/articles/PMC9124739/ /pubmed/35599248 http://dx.doi.org/10.1186/s13613-022-01017-5 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Research Scharf, Christina Weinelt, Ferdinand Schroeder, Ines Paal, Michael Weigand, Michael Zoller, Michael Irlbeck, Michael Kloft, Charlotte Briegel, Josef Liebchen, Uwe Does the cytokine adsorber CytoSorb(®) reduce vancomycin exposure in critically ill patients with sepsis or septic shock? a prospective observational study |
title | Does the cytokine adsorber CytoSorb(®) reduce vancomycin exposure in critically ill patients with sepsis or septic shock? a prospective observational study |
title_full | Does the cytokine adsorber CytoSorb(®) reduce vancomycin exposure in critically ill patients with sepsis or septic shock? a prospective observational study |
title_fullStr | Does the cytokine adsorber CytoSorb(®) reduce vancomycin exposure in critically ill patients with sepsis or septic shock? a prospective observational study |
title_full_unstemmed | Does the cytokine adsorber CytoSorb(®) reduce vancomycin exposure in critically ill patients with sepsis or septic shock? a prospective observational study |
title_short | Does the cytokine adsorber CytoSorb(®) reduce vancomycin exposure in critically ill patients with sepsis or septic shock? a prospective observational study |
title_sort | does the cytokine adsorber cytosorb(®) reduce vancomycin exposure in critically ill patients with sepsis or septic shock? a prospective observational study |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9124739/ https://www.ncbi.nlm.nih.gov/pubmed/35599248 http://dx.doi.org/10.1186/s13613-022-01017-5 |
work_keys_str_mv | AT scharfchristina doesthecytokineadsorbercytosorbreducevancomycinexposureincriticallyillpatientswithsepsisorsepticshockaprospectiveobservationalstudy AT weineltferdinand doesthecytokineadsorbercytosorbreducevancomycinexposureincriticallyillpatientswithsepsisorsepticshockaprospectiveobservationalstudy AT schroederines doesthecytokineadsorbercytosorbreducevancomycinexposureincriticallyillpatientswithsepsisorsepticshockaprospectiveobservationalstudy AT paalmichael doesthecytokineadsorbercytosorbreducevancomycinexposureincriticallyillpatientswithsepsisorsepticshockaprospectiveobservationalstudy AT weigandmichael doesthecytokineadsorbercytosorbreducevancomycinexposureincriticallyillpatientswithsepsisorsepticshockaprospectiveobservationalstudy AT zollermichael doesthecytokineadsorbercytosorbreducevancomycinexposureincriticallyillpatientswithsepsisorsepticshockaprospectiveobservationalstudy AT irlbeckmichael doesthecytokineadsorbercytosorbreducevancomycinexposureincriticallyillpatientswithsepsisorsepticshockaprospectiveobservationalstudy AT kloftcharlotte doesthecytokineadsorbercytosorbreducevancomycinexposureincriticallyillpatientswithsepsisorsepticshockaprospectiveobservationalstudy AT briegeljosef doesthecytokineadsorbercytosorbreducevancomycinexposureincriticallyillpatientswithsepsisorsepticshockaprospectiveobservationalstudy AT liebchenuwe doesthecytokineadsorbercytosorbreducevancomycinexposureincriticallyillpatientswithsepsisorsepticshockaprospectiveobservationalstudy |